TScan Therapeutics, Inc. Common Stock (TCRX) — Analysis Summary
TScan Therapeutics, Inc. Common Stock (TCRX) has a market cap of $67.31M with year-over-year revenue growth of +266.7%. Net margin stands at -1256.8%. The stock trades at a P/E ratio of -0.5.
Key Takeaways
- Revenue changed +266.7% year-over-year
- Net margin of -1256.8%
- P/E ratio of -0.5
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, TCRX posted revenue growth of +266.7% and trades at a P/E of -0.5.
TScan Therapeutics, Inc. Common Stock (TCRX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -46.3x — earnings do not cover interest payments
Operating margin at -1408.7% — severe operating losses
Net margin at -1360.6% — losses exceed revenue (possible one-time charges)
Revenue declined 11.5% vs the prior period.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
142
Headquarters
WALTHAM, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.